Format

Send to

Choose Destination
South Asian J Cancer. 2020 Jan-Mar;9(1):59-61. doi: 10.4103/sajc.sajc_246_19.

Role of Cresp® in the management of chemotherapy-induced anemia in cancer patients: A real-world clinical practice audit.

Author information

1
Department of Medical Oncology, Sum Hospital, Bhubaneswar, Odisha, India.
2
Department of Medical Oncology, RCC, Patna, Bihar, India.
3
Department of Medical Oncology, Yashoda Hospital, Secunderabad, Telangana, India.
4
Department of Medical Oncology, Asian Cancer Institute, Mumbai, Maharashtra, India.
5
Department of Medical Oncology, Kerala Institute of Medical Sciences, Trivandrum, Kerala, India.
6
Department of Medical Oncology, Apollo Specialty Hospital, Chennai, Tamil Nadu, India.
7
Department of Medical Oncology, Mohandai Oswal Hospital, Ludhiana, Punjab, India.
8
Department of Medical Oncology, BLK Superspeciality Hospital, Delhi, NCR, India.
9
Department of Medical Oncology, Naik Hospital, Baroda, Gujarat, India.
10
Department of Medical Oncology, Mumbai Oncocare Center, Mumbai, Maharashtra, India.
11
Department of Medical Oncology, Apollo Hospital, Kolkata, West Bengal, India.
12
Department of Pain and Palliative Care, Saroj Gupta Cancer Hospital, Kolkata, West Bengal, India.
13
Department of Medical Oncology, Batra Cancer Center, Delhi, NCR, India.
14
Department of Medical Oncology, Deenanath Mangeshkar Hospital, Pune, Maharashtra, India.
15
Department of Medical Oncology, Shalby Cancer and Research Institute, Ahmedabad, Gujarat, India.

Abstract

Introduction:

Anemia is a common, underestimated problem in cancer patients receiving myelosuppressive chemotherapy and has significant adverse effect on the quality of life and outcome. Darbepoetin has been shown to be effective in this setting, but controversy surrounds it actual use.

Methods:

We analyzed prospectively collected clinical practice data of patients receiving darbepoetin in a real-world setting for this retrospective audit. Patients with baseline hemoglobin (Hb) of <11 g/dl were included in this analysis. Their medical records were audited using a predetermined 35-point pro forma.

Results:

There were a total of 274 patients with advanced cancer receiving myelosuppressive chemotherapy who had baseline Hb <11 g/dl and who were given darbepoetin. Head-and-neck squamous cell carcinoma, lung cancer, and breast cancer were the most common cancers. Their median baseline Hb was 8.9 g/dl which rose to 11.2 g/dl at the end of commenced therapy, along with improved symptomatology. There were no new toxicities, and only two patients required discontinuation of darbepoetin due to toxicity.

Conclusion:

Darbepoetin is safe and effective in the prevention and management of anemia among patients receiving myelosuppressive chemotherapy.

KEYWORDS:

Hemoglobin; India; prophylaxis; quality of life; supportive care

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd Icon for PubMed Central
Loading ...
Support Center